These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

217 related items for PubMed ID: 8184174

  • 1. Octreotide in the management of active acromegaly due to inoperable growth hormone-secreting adenoma.
    Candrina R.
    Recenti Prog Med; 1994 Jan; 85(1):13-9. PubMed ID: 8184174
    [Abstract] [Full Text] [Related]

  • 2. First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial.
    Colao A, Pivonello R, Rosato F, Tita P, De Menis E, Barreca A, Ferrara R, Mainini F, Arosio M, Lombardi G.
    Clin Endocrinol (Oxf); 2006 Mar; 64(3):342-51. PubMed ID: 16487447
    [Abstract] [Full Text] [Related]

  • 3. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution.
    Jallad RS, Musolino NR, Salgado LR, Bronstein MD.
    Clin Endocrinol (Oxf); 2005 Aug; 63(2):168-75. PubMed ID: 16060910
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Experience in treating acromegalic patients with long-acting octreotide].
    Szücs N, Mészáros J, Czirják S, Mondok A, Varga I, Gláz E.
    Orv Hetil; 2002 May 12; 143(19 Suppl):1066-70. PubMed ID: 12063862
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The efficacy of octreotide LAR as firstline therapy for patients with newly diagnosed acromegaly is independent of tumor extension: predictive factors of tumor and biochemical response.
    Luque-Ramírez M, Portoles GR, Varela C, Albero R, Halperin I, Moreiro J, Soto A, Casamitjana R, Spanish Multicentre Group for the Study of Acromegaly.
    Horm Metab Res; 2010 Jan 12; 42(1):38-44. PubMed ID: 19798622
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Octreotide treatment of acromegaly. A randomized, multicenter study.
    Ezzat S, Snyder PJ, Young WF, Boyajy LD, Newman C, Klibanski A, Molitch ME, Boyd AE, Sheeler L, Cook DM.
    Ann Intern Med; 1992 Nov 01; 117(9):711-8. PubMed ID: 1416572
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The long-term efficacy of conventional radiotherapy in patients with GH-secreting pituitary adenomas.
    Minniti G, Jaffrain-Rea ML, Osti M, Esposito V, Santoro A, Solda F, Gargiulo P, Tamburrano G, Enrici RM.
    Clin Endocrinol (Oxf); 2005 Feb 01; 62(2):210-6. PubMed ID: 15670198
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.